SinoMab Grants 11.6 Million Share Options to Key Employees

An update from SinoMab Bioscience Ltd. ( (HK:3681) ) is now available.

SinoMab BioScience has granted 11,574,840 share options to two employees, including one senior management member, under its 2022 Share Option Scheme, with each option exercisable at HK$1.94 and convertible into one new share. The options, which vest in 25% tranches between 2027 and 2031 and are exercisable through 2036, are tied to the grantees’ roles, tenure and performance evaluations, reflecting the company’s use of equity incentives for retention and alignment while relying on existing lapse and cancellation rules instead of a separate clawback mechanism.

The senior management grantee’s options vest from March 2027 to March 2030 and are exercisable over nine years, while the other employee’s options vest from March 2028 to March 2031 with an eight-year exercise window ending in 2036. No financial assistance is being provided for option exercise, and the remuneration committee considers the scheme’s existing provisions sufficient to protect the company’s interests, signaling a measured approach to incentivizing key staff without adding leverage or additional clawback complexity.

The most recent analyst rating on (HK:3681) stock is a Sell with a HK$1.50 price target. To see the full list of analyst forecasts on SinoMab Bioscience Ltd. stock, see the HK:3681 Stock Forecast page.

More about SinoMab Bioscience Ltd.

SinoMab BioScience Limited is a Hong Kong–incorporated biopharmaceutical company focused on developing and commercializing innovative biologic therapies. Listed on the Hong Kong Stock Exchange, it operates through a group structure and relies on equity-based incentive schemes to attract and retain key talent in a competitive life sciences market.

Average Trading Volume: 5,191,732

Technical Sentiment Signal: Hold

Current Market Cap: HK$2.3B

See more data about 3681 stock on TipRanks’ Stock Analysis page.